iSpecimen Selected by U.S. Government and Researchers to Supply Human BioSpecimens for Advanced COVID-19 Research
Nov 22, 2021 By MarketDepth
iSpecimen Inc. (NASDAQ: ISPC) has reported that it has been contracted to support new advanced research on COVID-19 that seeks insights on its transmissibility, variants, outcomes and testing validity amongst multiple population segments. Within the past year, the company has partnered with multiple research and health care organizations on a range of projects that require a variety of COVID-19 samples which include saliva, nasal swabs and blood products. The company began work after the outbreak last year, sending serum samples to the U.S. Centers for Disease Control and Prevention to aide researchers to monitor antibody development for guidance on immunity. “COVID-19 has claimed more than 5 million lives, and it will require a lot of additional research to control the pandemic and improve society’s ability to contend with future outbreaks of infectious diseases,” said iSpecimen Founder and CEO, Christopher Ianelli, MD, Ph.D. “We embrace the challenge and are gratified that researchers are coming to us for the specific biospecimens they need from the types of patients they’re focusing on.”
Provided Human Specimens
iSpecimen has also supplied hundreds of human biospecimens to ongoing COVID-19 research conducted by the United States military. This includes positive and negative controls of SARS-CoV-2 samples. Helping researchers validate COVID-19 testing platform and understand fluctuations in patient antibody levels.
